Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research, and Chronic Lymphocytic Leukemia Research.
468 | FIRST‐IN‐HUMAN CART CELLS FOR ADULT T‐CELL LEUKEMIA/LYMPHOMA USING CTX130, A CD70‐TARGETED ALLOGENEIC CRISPR‐Cas9‐ENGINEERED CART‐CELLS. COBALT‐LYM STUDY COHORT
Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with <i>KMT2Ar</i> or <i>NPM1</i> Alterations
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
Single Cell RNA-Seq Reveals Intra-Tumoral Heterogeneity Relevant to Differentiation States and Outcomes Among Newly Diagnosed Acute Myeloid Leukemia Patients
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with <i>IDH 1/2</i> Mutations
Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models
Anti-Leukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody-Conjugate in Acute Myeloid Leukemia